PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the Arbeitsgemeinschaft internistische Onkologie (AIO).

Kirstin Breithaupt,D. Bichev,Mario Lorenz,Daniela Bohnen,Yasemin Dogan,Peter Schlattmann,Salah-Eddin Al-Batran,Markus Moehler,Peter C. Thuss-Patience

PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the Arbeitsgemeinschaft internistische Onkologie (AIO).

2017

Kirstin Breithaupt
D. Bichev
Mario Lorenz
Daniela Bohnen
Yasemin Dogan
Peter Schlattmann
Salah-Eddin Al-Batran
Markus Moehler
Peter C. Thuss-Patience

TPS4138 Background: VEGF inhibition in gastric cancer shows promising improvement of remission rate and progression-free survival (Ohtsu et al., JCO 2011). Pazopanib is an orally available tyrosine...

Keywords:

Cancer
Oxaliplatin
Internal medicine
Pazopanib
Oncology
VEGF receptors
Pathology
Phases of clinical research
Medicine
Fluorouracil
advanced gastric cancer
remission rate
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations